Table 1

Baseline characteristics in FINRISK, Health 2000 Cohort (H2000) and patients with type 2 diabetes (T2DM) in the Botnia

FINRISKH2000Botnia T2DM
OverallNon-OSAOSAP valuesOverallNon-OSAOSAP valuesOverallNon-OSAOSAP values
n=28 953n=27 739n=1214n=6605n=6370n=235n=1405n=1286n=119
Gender (male)13 792 (47.6%)12 915 (46.6%)877 (72.2%)1.26×10−68 2940 (44.6%)2768 (43.5%)172 (73.2%)3.8×10−19 735 (52.3%)651 (50.6%)84 (70.6%)4.6×10−5
Baseline age48.01 (13.2)47.95 (13.3)49.27 (11.3)8.2×10−5 53.8 (15.7)53.9 (15.8)50.7 (10.5)9.7×10−6 58.94 (11.5)59.20 (11.6)56.1 (9.9)1.6×10−3
Age at OSA diagnosis55.30 (10.4)55.81 (10.5)61.93 (10.7)
BMI26.74 (4.7)26.58 (4.5)30.34 (5.7)3.5×10−96 26.9 (4.7)26.8 (4.59)30.6 (5.74)1.5×10−20 29.26 (4.8)28.99 (4.7)32.20 (4.9)6.1×10−10
Current smoking6978 (24.2%)6666 (24.1%)312 (25.8%)0.201397 (21.3%)1340 (21.2%)57 (24.4%)0.27193 (13.7%)165 (12.8%)28 (23.5%)1.9×10−3
Systolic mm Hg135.7 (20.0)135.6 (20.1%)137.0 (17.5)7.8×10−3 135.0 (21.70)135.0 (21.8)136.1 (19.2)0.41144.6 (20.4)144.6 (20.4)145.0 (21.1)0.83
Diastolic mm Hg80.48 (11.6)80.33 (11.6)83.7 (11.2)6.4×10−25 81.7 (11.30)81.5 (11.3)86.5 (10.2)2.8×10−12 84.4 (10.4)84.0 (10.3)87.9 (10.3)1.3×10−4
CHOL mmol/L5.51 (1.1)5.51 (1.1)5.56 (1.0)0.075.9 (1.1)5.9 (1.1)6.0 (1.1)0.125.5 (1.1)5.6 (1.1)5.3 (1.0)3.4×10−3
LDL mmol/L3.352 (0.9)3.34 (0.9)3.50 (0.8)1.0×10−3 3.7 (1.1)3.7 (1.1)3.8 (1.0)0.293.2 (1.0)3.2 (1.0)3.1 (0.9)0.50
HDL mmol/L1.436 (0.4)1.44 (0.4)1.28 (0.3)9.0×10−53 1.3 (0.4)1.3 (0.4)1.2 (0.36)9.7×10−5 1.2 (0.3)1.2 (0.3)1.2 (0.3)3.3×10−3
Prevalent cases
CHD749 (2.6%)691 (2.5%)58 (4.8%)1.4×10−6 242 (3.7%)237 (3.7%)5 (2.1%)0.2743 (3.1%)38 (3.0%)5 (4.2%)0.41
Stroke324 (1.1%)311 (1.1%)13 (1.1%)0.98167 (2.5%)166 (2.6%)1 (0.4%)0.0621 (1.5%)20 (1.6%)1 (0.8%)1
T2DM1525 (5.3%)1403 (5.1%)122 (10.0%)4.2×10−14 381 (5.8%)362 (5.7%)19 (8.1%)0.161018 (72.5%)938 (72.9%)80 (67.2%)0.06
DKD20 (0.1%)20 (0.1%)015 (0.1%)5 (0.1%)013 (0.2%)2 (0.2%)1 (0.8%)0.23
CHD/T2DM238 (5.9%)214 (5.9%)24 (6.5%)0.7463 (7.5%)62 (8%)1 (1.6%)0.0843 (3.1%)38 (3.0%)5 (4.2%)0.41
DKD/T2DM9 (0.2%)9 (0.2%)012 (0.2%)2 (0.3%)013 (0.2%)2 (0.2%)1 (0.8%)
Incident cases
CHD2181 (7.5%)2035 (7.3%)146 (12.0%)1.9×10−9 576 (8.7%)546 (8.6%)30 (13.3%)0.03254 (18.2%)230 (18.0%)24 (20.1%)0.64
Stroke1325 (4.6%)1264 (4.6%)61 (5.0%)0.49352 (5.3%)338 (5.3%)14 (6.0%)0.77179 (12.8%)162 (12.7%)17 (14.3%)0.72
T2DM2481 (8.8%)2231 (8.0%)250 (20.6%)2.0×10−52 456 (6.9%)411 (6.5%)45 (19.1%)1.3×10−13 387 (27.5%)348 (27.1%)39 (32.8%)0.10
DKD296 (1.0%)262 (0.9%)34 (2.8%)7.9×10−10 112 (1.7%)109 (1.7%)3 (1.3%)0.8091 (6.5%)77 (6%)14 (11.8%)0.03
CHD/T2DM657 (16.4%)584 (16.1%)73 (19.6%)0.10154 (18.4%)141 (18.2%)13 (20.3%)0.81254 (18.2%)230 (18.0%)24 (20.1%)0.64
DKD/T2DM151 (3.8%)128 (3.5%)23 (6.2%)0.0243 (5.1%)42 (5.4%)1 (1.6%)0.2491 (6.5%)77 (6%)14 (11.8%)0.03
  • Baseline demographics and clinical characteristics p values were based on χ2 test. Fisher’s exact test was used if the sample size was ≤5. For continuous variables, we used Student’s t-test. Data are mean (SD) or number (%). BMI, body mass index; CHOL, total cholesterol; CHD, coronary heart disease; CHD/T2DM, coronary heart disease among patients with type 2 diabetes; DKD, diabetic kidney disease; DKD/T2DM, diabetic kidney disease among patients with type 2 diabetes; LDL, low-density lipoprotein; OSA, obstructive sleep apnoea.